BTIG Research Cuts Tvardi Therapeutics (NASDAQ:TVRD) Price Target to $5.00

Tvardi Therapeutics (NASDAQ:TVRD) had its price objective lowered by BTIG Research to $5.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also issued reports on TVRD. HC Wainwright began coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 target price on the stock. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. Finally, Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $2.10 on Thursday. The firm has a market cap of $19.70 million, a price-to-earnings ratio of -0.68 and a beta of 0.39. Tvardi Therapeutics has a 52-week low of $1.50 and a 52-week high of $43.65. The firm has a 50 day moving average price of $2.76 and a two-hundred day moving average price of $3.38.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). As a group, equities research analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new position in Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the second quarter valued at $43,000. Headlands Technologies LLC bought a new stake in Tvardi Therapeutics in the second quarter valued at $80,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at about $92,000. Finally, Arax Advisory Partners raised its holdings in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the period. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.